.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,886,035

« Back to Dashboard
Patent 5,886,035 protects ZIOPTAN and is included in one NDA. There has been one Paragraph IV challenge on Zioptan.

This patent has nineteen patent family members in thirteen countries.

Summary for Patent: 5,886,035

Title: Difluoroprostaglandin derivatives and their use
Abstract:A fluorine-containing prostaglandin derivative of the formula (1) (or a salt thereof) and a medicine containing it, particularly, a preventive or therapeutic medicine for an eye disease: ##STR1## wherein A is a vinylene group or the like, R.sup.1 is an aryloxyalkyl group or the like, R.sup.2 and R.sup.3 are hydrogen atoms or the like, and Z is OR.sup.4 (wherein OR.sup.4 is a hydrogen atom or an alkyl group) or the like.
Inventor(s): Shirasawa; Eiichi (Ikoma, JP), Kageyama; Masaaki (Ikoma, JP), Nakajima; Tadashi (Ikoma, JP), Nakano; Takashi (Yokohama, JP), Mori; Nobuaki (Yokohama, JP), Sasakura; Hideshi (Yokohama, JP), Matsumura; Yasushi (Yokohama, JP), Morizawa; Yoshitomi (Yokohama, JP)
Assignee: Asahi Glass Company Ltd. (Tokyo, JP) Santen Pharmaceutical Co., Ltd. (Osaka, JP)
Application Number:08/993,017
Patent Claim Types:
see list of patent claims
Compound; Use;
Patent Metrics:
Source: PatentQuant.com
Field: Organic fine chemistry
Back Citations: 1st percentile
Forward Citations: 1st percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Oak Pharms Inc
ZIOPTAN
tafluprost
SOLUTION/DROPS;OPHTHALMIC202514-001Feb 10, 2012RXYes5,886,035► subscribeYY REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATEINTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 5,886,035

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan8-348614Dec 26, 1996
Japan9-074054Mar 26, 1997
Japan9-172477Jun 27, 1997

Non-Orange Book Patents for Patent: 5,886,035

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,985,920 Difluoroprostaglandin derivatives and their use► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 5,886,035

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria225770► subscribe
Canada2225761► subscribe
China1108289► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc